BB Biotech reports 5.6% NAV increase in Q3 2026

BB Biotech AG reported a 5.6% increase in its Net Asset Value (NAV) in CHF for the third quarter of 2026. While the company's stock rose by 6.5%, it trailed the Nasdaq Biotechnology Index (NBI), which gained 12% during the same period.

The company recorded a net profit of CHF 175 million for the third quarter, compared to CHF 448 million in the previous year's quarter. However, for the first nine months of 2026, total net profit reached CHF 605 million, a significant increase from CHF 106 million in the same period last year.

Key drivers included three US drug approvals for portfolio companies and the completion of acquisitions involving Crinetics Pharmaceuticals and Nuvalent. BB Biotech reinvested approximately CHF 280 million from M&A proceeds, building twelve new positions and exiting eight holdings, bringing its total portfolio to 43 companies as of late September.